Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Core Insights - Celldex reported strong enthusiasm for its drug barzolvolimab, highlighting its efficacy across multiple indications and the completion of enrollment in Phase 3 studies ahead of schedule [2][5][6] - The company anticipates significant data readouts in 2026, including topline data from Phase 3 studies in chronic spontaneous urticaria (CSU) and additional studies in prurigo nodularis and atopic dermatitis [2][5][10] - Celldex is preparing for a Biologics License Application (BLA) filing for barzolvolimab in CSU, which could position the company as a leader in immunology [2][5] Recent Program Highlights - Barzolvolimab is a humanized monoclonal antibody targeting mast cells, crucial for inflammatory responses in conditions like chronic urticarias [3] - Enrollment in Phase 3 CSU studies (EMBARQ-CSU1 and EMBARQ-CSU2) was completed with 1,939 patients across 43 countries, making it the largest program for antihistamine refractory CSU [5][6] - The Phase 3 studies aim to establish the efficacy and safety of barzolvolimab in adult patients who remain symptomatic despite existing treatments, with topline data expected in Q4 2026 [5][6] Financial Highlights - As of December 31, 2025, Celldex had cash, cash equivalents, and marketable securities totaling $518.6 million, down from $583.2 million at the end of Q3 2025, primarily due to increased operating expenses [10][11] - Total revenue for Q4 2025 was $0.1 million, with annual revenue of $1.5 million, a decrease from $1.2 million and $7.0 million in the same periods of 2024 [11] - Research and development expenses rose to $75.3 million in Q4 2025 and $245.1 million for the year, reflecting increased clinical trial costs and employee headcount [12][14] Future Guidance - Celldex expects its current cash position to be sufficient to meet working capital needs and fund operations through 2027 [17] - The company is set for a landmark year in 2026 with multiple clinical readouts and data presentations planned [5][10]